ACP
Acuta Capital Partners Portfolio holdings
AUM
$71.6M
1-Year Return
169.78%
This Quarter Return
+56.19%
1 Year Return
+169.78%
3 Year Return
+1,553.75%
5 Year Return
+4,509.01%
10 Year Return
+155,159.98%
AUM
$178M
AUM Growth
+$40.1M
(+29%)
Cap. Flow
+$6.94M
Cap. Flow
% of AUM
3.91%
Top 10 Holdings %
Top 10 Hldgs %
56.23%
Holding
55
New
11
Increased
14
Reduced
9
Closed
15
Top Buys
| 1 |
Tourmaline Bio
TRML
|
$6.07M |
| 2 |
Ocular Therapeutix
OCUL
|
$5.84M |
| 3 |
Sarepta Therapeutics
SRPT
|
$5.31M |
| 4 |
Mersana Therapeutics
MRSN
|
$5.26M |
| 5 |
Revolution Medicines
RVMD
|
$4.59M |
Top Sells
| 1 |
Apellis Pharmaceuticals
APLS
|
$10.1M |
| 2 |
Ventyx Biosciences
VTYX
|
$7.13M |
| 3 |
Syndax Pharmaceuticals
SNDX
|
$4.31M |
| 4 |
Alkermes
ALKS
|
$3.54M |
| 5 |
Replimune Group
REPL
|
$2.57M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
51
Replimune Group
REPL
$494M
| – | – |
-150,000
| Closed | -$2.57M |
|
52
Rezolute
RZLT
$696M
| – | – |
-310,000
| Closed | -$409K |
|
|
53
Syndax Pharmaceuticals
SNDX
$1.47B
| – | – |
-297,035
| Closed | -$4.31M |
|
|
54
Ventyx Biosciences
VTYX
$180M
| – | – |
-205,377
| Closed | -$7.13M |
|
|
MRNS
55
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| – | – |
-19,500
| Closed | -$157K |
|